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SEBACEOUS GLAND RESPONSE IN MAN TO THE ADMINISTRATION
OF TESTOSTERONE, A4-ANDROSTENEDIONE, AND
DEHYDROISOANDROSTERONE*
PETER E. POCHI, M.D. AND JOHN S. STRAUSS, M.D.
Previous studies have demonstrated that the
sebaceous gland in man is readily stimulated
by testosterone (1, 2), and the finding that
orehieetomy leads to a reduction in sebaceous
gland activity (3) affords evidence that tes-
tosterone is primarily responsible for sebaceous
gland stimulation in the maje. However,
the role of other endogcnous androgcns
in the maintenance of sebaceous gland
function has not been clearly established.
In a prior report we presented some pre-
liminary data on the sebaceous gland response
to the administration of dchydroiscandroste-
rone (4). This study presents results of the
effect on schaceous gland secretion from the
administration of 5-androstenedionc and de-
hydroisoandrosterone, androgens which are pri-
marily secreted by the adrenal cortex. Their
sebum stimulating potency is compared with
that resulting from testosterone administra-
tion.
METHOD AND MATERIALS
Various androgens were administered to 27 adult
male subjects in 45 separate drug trials and their
cifect on sebaceous gland secretion studied by an
in-vivo assay which has been described previously
(2). This consists of the administration of ethinyl
estradiol, 1 mg orally daily, until maximum sup-
pression of sebaccous secretion occurs, followed by
the concomitant administration of the test andro-
gen. This assay proccdurc utilizes the observation
that estrogen and androgen show no apparent
competitive inhibition at the sebaceous gland
site (1), and an increase in sehum output during
combined estrogen-androgen administration re-
sults from the stimulatory effect of the androgen
(2).
The following androgens were assayed:
a) methyl testosterone; 5, 10, 25 and 100 mg
orally daily, for 8—10 weeks.
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h) testosterone, aqueous suspension; 25 mg
intramuscularly, 3 times weekly, for 10—11 weeks.
c) testosterone propionate in oil; 25 and
100 mg intramuscularly, 3 times weekly, for 7—
11 weeks.
d) a5-androstenedione, aqueous suspension;
25 and 100 mg intramuscularly, for 10—11 weeks.
e) dchydroisoandrosterone, aqueous suspen-
sion; 25 and 100 mg intramuscularly, for 8—10
weeks.
Ta each subject sebum production was measured
approximately weekly during each drug trial by a
gravimetric procedure (5). The androgenic re-
sponse was determined by calculating the quanti-
tative difference in sebum production between the
average of the last 3 tests in the estrogen suppres-
sion period and the average of the last 3 tests
during combined estrogen-androgen administra-
tion.
RESULTS
Tables I, IT, III and IV show the sebaceous
gland response to the administration of oral
methyl testosterone, intramuscular testosterone
preparations, 5-nndrostenedione, and dehydro-
isoandrosterone, respectively. An increase in
sebum production was observed in each separate
drug trial with all the compounds tested. On
an equivalent weight basis, methyl testosterone
was the most potent androgen tested. Of the
dosages used, the greatest rise in sebum secre-
tion was soon with 100 mg of methyl testoster-
one daily, and the least effect occurred with 25
mg of dehydroisoandrosterone 3 times weekly.
However, oven in the latter instance, this rep-
resented a 40% increase in sebum output.
Statistical analysis of the paired data for each
compound and dosage used showed a signifi-
cant increase (P < .01) in sebum production
with all doses of methyl testosterone except for
the 100 mg daily dose. That the highest dose
did not produce a statistically significant re-
sponse was due largely to the presence of only
two subjects in this group. Significant increases
wore also observed with testosterone (P < .01)
and with testosterone propionate, 25 mg three
times weekly (P < .05 > .02). The increases
ln sebum production resulting from other doses
of the androgens used could not be shown to
have statistical significance even though, for cx-
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TABLE I
Sebaceovs gland response to the oral administration
of methyl testosterone
TABLE II
&baceous gland response to the intramuscular
administration of testosterone
Sebum production
(nig lipid/JO cm2/3 hr) Sebum production(xng lipid/JO cm2/3 hr)
Daily dose
5 mg
10 mg
Subject
2
3
Mean
4
5
6
7
8
9
10
11
12
13
14
15
Mean
Estrogen
suppression
0.56
0.51
0.39
0.49
1.98
1.77
1.49
1.07
0.99
0.91
0.74
0.71
0.68
0.67
0.53
0.22
0.98
Testos-
terone
admin-
istration
1.60
1.67
1.27
1.51
3.60
3.40
2.97
1.98
2.76
1.66
2.39
2.56
2.45
0.88
0.85
0.99
2.21
Increase
in sebum
(mg)
1.04
1.16
0.88
1.02
1.62
1.63
1.48
0.91
1.77
0.75
1.65
1.85
1.77
0.21
0.32
0.77
1.23
Dose Subject
Estro-
pression
arlmin-
Increase
se1m
(mg)
Testosterone, 25 mg,
3 times weekly
20
11
21
19
Mean
1.41
0.84
0.76
0.68
0.92
2.10
2.05
1.50
1.29
1.74
0.69
1.21
0.74
0.61
0.82
Testosterone propio-
nate, 25mg, 3
times weekly
20
21
22
10
19
23
Mean
1.21
0.82
0.76
062
0.51
0.47
0.73
1.67
1.39
1.25
2.38
0.78
0.85
1.39
046
0.57
0.49
1.76
0.27
0.38
0.66
Testosterone propio-
nate, 100 mg, 3
times weekly
23
10
22
Mean
1.13
0.71
0.39
0,74
2.11
3.59
1.32
2.34
0.98
2.88
0.93
1.60
25mg 16
1
17
3
Mean
1.02
0.68
0.67
0.39
0.69
2.45
2.07
1.46
2.04
2.01
1.43
1.39
0.79
1.65
1.32
100mg 18
19
Mean
0.91
0.71
0.81
3.66
1.39
2.53
2.75
0.68
1.72
TABLE III
Sebaceous gland response to the intrantuscular
administration of A4-androsteneclione
Sebum production
(mg lipid/JO cm2/3 hr)
ample, the 100 mg doses of methyl testosterone,
testosterone propionate and 4-androstenedione
all resulted in a greater than 200% increase in
sebum production. The small number of sub-
jects in most of the groups and the considerable
variation from individual to individual in
sebum production levels prior to androgenic
stimulation prevented statistical validation in
these several instances. For these same rea-
sons, dose-response relationships for the in-
dividual androgens could not be established by
statistical means.
Despite these statistical limitations, it was
Dose Subject
Estro-
gm
sup-
pression
-An-
droste-
nedionc
admin-
istra—
tion
Increase
in
sebum
(mg)
25mg, 3 times
weekly
24
25
10
Mean
1.58
1.46
0.99
1.34
2.33
1.71
1.74
1.93
0.75
0.25
0.75
0.58
100 mg,3 times 26
weekly 27
I 12
Mean
0.81
0.31
0.29
0.47
1.92
0.93
1.82
1.56
1.11
0.62
1.53
1.0
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still observed that the weaker androgens, &-
androstenedione and dehydroisoandrosterone,
were relatively effective in stimulating sebum
secretion when compared to testosterone. For
example, of the parenterally administered an-
drogens in the dosage of 25 mg three times
weekly, it was found that 4-androstenedione
was 70% as active as testosterone and 85% as
active as testosterone propionate. Dehydroiso-
androsterone was 55% and 70% as potent as
TABLE IV
Sebaceous gland response to the intramuscular
administration of dehydroisoandrosterone
Sebum production(mg lipid/is cm'/3 hr)
Dose Subject
Estro-
gen
sup-
pression
Dehy-
dro-
isoan-
droster-
one ad-
minis-
tration
1.83
1.77
1.24
1.61
Increase
-
,n
sebum
(mg)
0.41
0.75
0.23
0.46
25mg,3times
weekly
20
11
26
Meaa
1.42
1.02
1.01
1.15
lOOmg,3times
weekly
20 1.25
22 0.39
Mean 0.82
2.08 0.83
1.49 1.10
1.79 0.97
testosterone and testosterone .propionate, re-
spectively.
Eleven subjects received more than one trial
of a different androgea, and the effect of these
multiple androgen assays in given individuals
is shown in Table V. In most instances, these
subjects showed appropriate differences in re-
sponse depending upon the particular androgen
and dose used.
DISCUSSION
It had been observed previously that sebum
production in adult males castrated prior to
puberty did not differ significantly from that of
men castrated after puberty although in both
instances sebum levels were higher than those
of prepuberal children (6). Since androgen is
the only known stimulus for direct sebaeeous
gland development and secretion (2), it seemed
reasonable to infer that adrenoeortical androgen
was responsible in part for sebaceous gland
stimulation. Additional support for this pos-
sibility was afforded by the demonstration that
the oral administration of prednisone can cause
a decrease in sebum output in male castrates
and in females, and it has been suggested that
this effect is due to suppression of adrenoeorti-
cal androgons (7).
Thus, the findings in the present study of a
significant sebaceous gland stimulating effect
from zX5-androstenedione and dehydroisoandros-
terone, androgens secreted by the adrenal eor-
TABLE V
Comparative sebaceous gland response in individual subjects
Increase in sebum production (mg)
Methyl testosterone (mg/day)
1.04
0.88
25
1.39
1.65
Testosterone
propionale (mg/week)
75 30010
1.65
1.85
1.77
Subject
1
3
10
11
12
19
20
21
22
23
26
100
0.68
Testos-
terone (75
mg/week)
1.21
0.61
0.69
0.74
A5-Androstenedione
(mg/week)
75 300
0.75
1.53
1.11
1.76
0.27
0.46
0.57
0.49
0.38
2.88
0.93
0.98
Dehydroisoan-
drostecone (mg/week)
75 300
0.75
0.41 0.83
1.10
0.23
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tex, offer further evidence of a role for these
steroids in sebaceous gland control. The daily
secretory rate for 4-androstenedione has been
estimated to be 2.7—3.6 mg per day (8, 9) which
is less than the doses used in this study. How-
ever, the lower dose of dchydroisoandrosterone
assayed, i.e. 25 mg 3 times weekly, is in the
physiologic range for dehydroisoandrosterone
secretion which has been determined to range
from 7 to 25 mg daily (10, 11). It may not be
possible to relate precisely the physiologic
secretion rate for adrenal androgens to the
doses administered experimentally. For ex-
ample, the concentration of dehydroisoandros-
terone sulfate in peripheral blood is approxi-
mately 100 times that of unconjugated
dehydroisoandrosterone (12, 13), with conjuga-
tion of dehydroisoandrosterone to sulfate oc-
curring not only in the liver but in the adrenal
cortex, itself, prior to its secretion (14). Dc-
hydroisoandrosterone enters this large dehydro-
isoandrosteronc-sulfate pool and, thus, the
amount of conjugated steroid reaching periph-
eral tissues is considerable. It is noteworthy in
this regard that Drueker et al. reported an in-
crease in sebum production in 2 subjects ad-
ministered dehydroisoandrosterone sulfate (15).
Also, in vitro studies have demonstrated the
conversion in human skin of dehydroisoandros-
terone sulfate to free dehydroisoandrosterone,
A4-androstenedione, and testosterone (16).
Since both A'-androstenedione and dehydro-
isoandrosterone are precursors for testosterone
synthesis (17), it is not certain whether seba-
ceous gland stimulation from adrenal androgens
is the result of direct glandular stimulation or
of in-vivo conversion to testosterone prior to
their reaching the sebaeeuus gland site. In this
connection, several recent reports have shown
that human skin can convert dehydroisoandros-
terone and/or 4-androstenedione to testoster-
one in vitro (18—20). To what extent these bio-
chemical transformations in the skin occur in
vivo is not known nor is there any information
available from these in-vitro studies as to sites
within the skin for such reactivity. However,
Baillie and co-workers have demonstrated his-
tochemically the presence of a variety of hy-
droxysteroid dehydrogenases in human skin,
among them 3,3- and 17/3-dehydrogenases, and
the most intense localization for this activity
was the sebaceous gland (21). Furthermore,
studies on the local application of steroids to
the chick comb, another androgen-responsive
tissue, show that A'-androstencdione and de-
hydroisoandrosterone have a significant local
stimulating effect (22, 23).
The relative androgenic potency of the
steroids administered systemically in this study
is in general agreement with that observed in.
animal assays utilizing the response to stimu-
lation of the seminal vesicles, the ventral pros-
tate gland and the levator ani of rats (24—26)
and of the cluck comb (27, 28). One exception!
is that parenterally administered testosterone
propionate is 2—7 times as potent as testoster-
one in animal assays (25, 26); whereas, we
found the sebaccous gland to respond some-
what less actively to it than to testosterone.
sUMMARY
An in vivo human assay was used to de-
termine the relative stimulating effect of vari-
ous androgens on sebaceous gland secretion.
The androgens studied were methyl testoster-
one, testosterone, testosterone propionate, S—
androstenedione, and dehydroisoandrosteronc.
The testosterones were found to be the most
potent androgens tested. However, the ad-
ministration of &-androstenedione and dehy-
droisoandrosterone, androgens primarily se-
creted by the adrenal cortex, also resulted in
sebaceous gland stimulation, and this finding
suggests a role for these weaker androgens in
the control of sebaceous gland function.
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